 Shares in CytoSorbents NASDAQ: CTSO are surging 12 higher at 11:30 a.m. EDT on Wednesday after the company announced it will offer 5.3 million shares to the public at 9.50 per share. The influx of capital from this share offering will substantially improve CytoSorbents liquidity, providing it with additional flexibility to support efforts to increase demand for its blood purification technology, CytoSorb. Worldwide, CytoSorb has been used to purify blood to reduce the risk of complications in more than 1,200 patients in over 30 countries, including in the U.S., where the Food and Drug Administration FDA granted emergency use authorization for CytoSorb in COVID-19 patients in April. 